Adagio Therapeutics Reports First Quarter 2022 Financial Results
$532.2 Million in Total Cash at Quarter End; Strong Balance Sheet Expected to Support Operations into Second Half of 2024 Additional Data from Adintrevimab Phase 2/3 STAMP Treatment Trial to be...
Source: marketscreener.com